Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
[HTML][HTML] Mechanisms of SARS-CoV-2 entry into cells
The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
The emergence of the Omicron variant of SARS-CoV-2 is an urgent global health concern. In
this study, our statistical modelling suggests that Omicron has spread more rapidly than the …
this study, our statistical modelling suggests that Omicron has spread more rapidly than the …
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Summary Background Several SARS-CoV-2 variants of concern have been identified that
partly escape serum neutralisation elicited by current vaccines. Studies have also shown …
partly escape serum neutralisation elicited by current vaccines. Studies have also shown …
The biological and clinical significance of emerging SARS-CoV-2 variants
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
spike protein mutations that are influencing the epidemiological and clinical aspects of the …
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients
D Geers, MC Shamier, S Bogers, G den Hartog… - Science …, 2021 - science.org
The emergence of SARS-CoV-2 variants harboring mutations in the spike (S) protein has
raised concern about potential immune escape. Here, we studied humoral and cellular …
raised concern about potential immune escape. Here, we studied humoral and cellular …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
A Pegu, SE O'Connell, SD Schmidt, S O'Dell… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …
vaccine-induced protective immune responses, particularly as antibody titers wane over …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …